Oura Targets September IPO With Projected $16 Billion Valuation
The smart ring maker aims to raise up to $3 billion as it transitions from a niche biohacking tool to a mainstream health brand.
Oura is reportedly preparing for a U.S. initial public offering as early as September 2026. The move signals a major scaling effort for the smart ring manufacturer as it seeks to solidify its position in the competitive wearables market.
According to reports from TechCrunch, the company is targeting a valuation exceeding $16 billion, a substantial jump from its $10.9 billion valuation recorded in September 2025. Oura aims to raise up to $3 billion through the offering, with a significant portion of the stock expected to be sold by existing investors. This follows a confidential IPO filing submitted by the company on May 21, 2026.
The Shift to Mainstream Health
Oura has evolved its market positioning from a specialized biohacking tool favored by executives into a broad consumer brand focused on sleep and recovery. This transition comes as the wearables sector expands beyond wrist-based trackers. However, the company now faces intensifying competition from tech giants and specialized rivals. Samsung has entered the fray with the Galaxy Ring, while Whoop—which reached a valuation of approximately $10.1 billion in March 2026—has expanded its tracking capabilities into thyroid and hormone health.
Market Implications and Risks
A successful debut at a $16 billion-plus valuation would serve as a strong endorsement of the smart ring category, proving that standalone health rings can maintain high premiums despite competition from diversified ecosystems like Samsung's. It would validate the consumer appetite for form-factor alternatives to the smartwatch.
However, the timing of the IPO coincides with legal headwinds. In August 2026, a class-action lawsuit was filed alleging that Oura misled consumers regarding the accuracy of its sleep-tracking features. While an Oura spokesperson stated that the company's sleep staging has been validated against polysomnography—the gold standard for clinical sleep studies—and noted the ring is not a medical device, the litigation could weigh on investor sentiment during the roadshow.
What to Watch
Investors will be closely monitoring whether the legal challenges regarding tracking accuracy impact the final offering price or the timing of the debut. Additionally, the market will look for clarity on how Oura intends to defend its market share against the aggressive expansion of Whoop and the hardware integration of Samsung.